Targeting this pathway has been demonstrated to impair androgen-stimulated tumor cell growth, suggesting that targeting this signaling pathway could be a potential therapeutic approach to treat ER-/HER2+ breast cancers [55]. Here, ESR1 is linked to breast carcinoma.